Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol

JAMA Cardiol. 2019 May 1;4(5):473-477. doi: 10.1001/jamacardio.2019.0771.

Abstract

These 4 hypothetical cases highlight some of the new features in the 2018 American Heart Association/American College of Cardiology multisociety cholesterol management guidelines. Topics include management issues in a secondary prevention patient judged to be at very high risk of another event, a patient with familial hypercholesterolemia with a low-density lipoprotein cholesterol level of 190 mg/dL or greater (to convert to millimoles per liter, multiply by 0.0259), a primary prevention patient with intermediate (7.5%-19.9%) 10-year atherosclerotic cardiovascular risk, and a patient who has statin-associated adverse effects. A multiple-choice format is used to engage clinicians in selecting the best choice based on guidance from the new 2018 cholesterol management guidelines.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • American Heart Association / organization & administration
  • Anticholesteremic Agents / therapeutic use
  • Atherosclerosis / complications
  • Atherosclerosis / prevention & control*
  • Cardiology / organization & administration
  • Cardiovascular Diseases / prevention & control
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / drug effects*
  • Ezetimibe / therapeutic use
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / drug therapy*
  • Male
  • Middle Aged
  • Practice Guidelines as Topic / standards*
  • Primary Prevention / standards
  • Secondary Prevention / standards
  • United States / epidemiology

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Ezetimibe